Catalent (CTLT) Coverage Initiated by Analysts at Goldman Sachs Group
Goldman Sachs Group began coverage on shares of Catalent (NYSE:CTLT) in a report published on Wednesday morning, MarketBeat.com reports. The firm issued a buy rating and a $50.00 target price on the stock.
A number of other analysts have also recently commented on the company. Zacks Investment Research cut Catalent from a buy rating to a hold rating in a research report on Thursday, January 18th. First Analysis assumed coverage on Catalent in a research report on Friday, January 5th. They set an equal weight rating for the company. Royal Bank of Canada assumed coverage on Catalent in a research report on Wednesday, December 13th. They set an outperform rating and a $46.00 price objective for the company. ValuEngine cut Catalent from a buy rating to a hold rating in a research report on Friday, December 1st. Finally, BidaskClub cut Catalent from a buy rating to a hold rating in a research report on Tuesday, November 14th. Six investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has an average rating of Buy and an average target price of $45.00.
Catalent (NYSE:CTLT) opened at $46.15 on Wednesday. Catalent has a one year low of $25.89 and a one year high of $46.40. The company has a quick ratio of 2.49, a current ratio of 2.91 and a debt-to-equity ratio of 2.01. The firm has a market capitalization of $6,130.00, a price-to-earnings ratio of 53.66, a PEG ratio of 2.82 and a beta of 1.41.
In related news, Director Uwe Roehrhoff purchased 7,500 shares of the business’s stock in a transaction on Tuesday, November 21st. The stock was acquired at an average price of $39.22 per share, with a total value of $294,150.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John R. Chiminski sold 181,458 shares of the business’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. Insiders own 1.70% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CTLT. Janus Henderson Group PLC bought a new position in shares of Catalent in the second quarter worth about $239,629,000. Eagle Asset Management Inc. boosted its stake in shares of Catalent by 290.9% in the third quarter. Eagle Asset Management Inc. now owns 1,153,710 shares of the company’s stock worth $47,636,000 after acquiring an additional 858,600 shares during the period. Macquarie Group Ltd. boosted its stake in shares of Catalent by 60.2% in the second quarter. Macquarie Group Ltd. now owns 1,786,764 shares of the company’s stock worth $62,715,000 after acquiring an additional 671,429 shares during the period. Renaissance Technologies LLC bought a new position in shares of Catalent in the second quarter worth about $23,092,000. Finally, Emerald Advisers Inc. PA boosted its stake in shares of Catalent by 1,072.2% in the third quarter. Emerald Advisers Inc. PA now owns 604,207 shares of the company’s stock worth $24,120,000 after acquiring an additional 552,663 shares during the period. 98.88% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Catalent (CTLT) Coverage Initiated by Analysts at Goldman Sachs Group” was originally reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://theolympiareport.com/2018/01/25/catalent-ctlt-coverage-initiated-by-analysts-at-goldman-sachs-group.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.